- Email: [email protected]
Drug Recalls
8 8o
Drug Recalls
The following data have been compiled from the Federal Food and Drug Administration Weekly Recall Reports covering the period November 11, 1969, to December 8, 1969. Pharmacists and others possessing drug inventories are reminded to cheCk their stock again to be certain that they do not have any of the products on this list. Anyone who has additional facts on any of th e listed recalls which he fe els will assist in completing the recall is urged to send such data to the editor of this Joumal. Fi rm Identified on Product Label
Product
Lot Number
Quantity
Recall Reason
Product Distribution
ehlor-Tel time release capsules (chlorpheniramine maleate USP 12 mg), 1,000's
Garden (Hackensack, N.J.) Wollins (Farmingdale, N.Y.)
6954
448,000 capsules
Subpotent (81-96.3% of declared potency)
Michigan New Jersey New York Pennsylvania
Delfeta-Sed plus T steady tabs sustained release tablets (dl-methamphetamine hydrochloride USP 30 mg, amobarbital USP 120 mg, thyroid USP 48.6 mg), 30's
Eastern Research (Baltimore, Md.)
All lots
976,260 tablets
Drug efficacy study implementation
National
Deprol tablets (meprobamate NF 400 mg, benactyzine hydrochloride 1 mg), samples of 12's and 100's
Wallace (Cranbury, N.J.)
All starting 6E through 6L; all starting 7A and 7B through 7B536, 23-2-789 through 23-2-856
80,300,000 tablets
Subpotent (83-92% of declared benactyzine)
National
Oolamine injection (ammonium sulfate 0.75%, benzyl alcohol NF 0.75%, sodium chloride U$P 0.48%), 10 ml
Harvey (Philadelphia, Pa.)
All lots
All since 1939
Drug efficacy study implementation
National
Estrogenic substance natural injection 2 mg/ml, 10 ml and 30 ml
Taylor (Decatur, III.)
21179
15,830 ml
Subpotent (68.5-82.5% of declared potency
California Canada
Furacin gauze pads (nitrofurazone NF 0.2%), 12's
Eaton (Norwich, N. Y.)
665165 to 665197, 665208 to 665231
41,200 packages
Excessive residues of ethylene oxide
National
locort cream (hydrocortisone USP 1/4%, iodochlorhydroxyquin 3%), 10z
Doak (Westbury, N. Y.)
All lots
97 tubes
Su perpotent (126-132% of declared hydrocortisone)
Connecticut Indiana Massachusett s New Jersey New York Rhode Island
Canadian Pharmaceutical Association Survey Issued THE AVERAGE PRESCRIPTION drug price in Canada for 1968 was $3.67-an increase of 10 cents over 1967 and the lowest during the past three years. According to the Canadian Pharmaceutical Association's 27th Annual Survey of Retail Pharmacy, published in the October 1969 edition of The Canadian Pharmaceutical Journal, the 1968 average of $3.67 compares with $3.57 in 1967, $3.46 in 1966 and $3.32 in 1965. Sales in Canadian pharmacies during 1968 increa~ed 8.5 percent with the greatest increase in sales resulting from prescription receipts which increased 10.6 percent while other sales increased 7.6 percent according to the CPhA survey. The 1968 average number of prescriptions dispensed in the pharmacy annually increased 7.7 percent over 1967 to a total of 14,830. The survey also showed that the average hours per week a pharmacy was open dropped slightly-from 65 in 1967 to 64 in 1968-but that the average number of hours worked by the proprietor increased from 48 to 50 hours.
Know Your Suppliers Much has been said recently about "research," "product development," "quality control" and "professional services" offefled by the pharmaceutical industry. Evidenoe to support these activities has been often presented by the industry as a whole, but we feel that not ,e nough of us "really know" enough about many of the major prescription drug manufacturers, much less those firms that specialize in other types of pharmaceutical products and servioes. To present the "true personality" of a variety of different pharmaceutical companies-and we believe that each has its own personality just as each of us has a distinct personality-this Journal has offered to share the cost of publishing a series of four-page articles with various firms . In each of these features (see page 118) , readers will see the unique capabilities and seTvices of many firms whose products they use regularly. To be sure, som,e of the data will apply equally to all reputable firms, but even here, we hope the reader will better understand the American pharmaceutical industry without whose efforts we would not have many of the life-saving drugs we are able to provide to the public. The editorial content of each article is that of the firm and the selection of illustrations was made by the company. Thus, a careful review of each featured manufactur1er's presentation will truly reflect the achievements as well as the philosophy of that particular firm. We urge readership reaction to the series as it progress,es. The Editor
Vol. NS10, No.2, February 1970
117
Drug Recalls
The following data have been compiled from the Federal Food and Drug Administration Weekly Recall Reports covering the period November 11, 1969, to December 8, 1969. Pharmacists and others possessing drug inventories are reminded to cheCk their stock again to be certain that they do not have any of the products on this list. Anyone who has additional facts on any of th e listed recalls which he fe els will assist in completing the recall is urged to send such data to the editor of this Joumal. Fi rm Identified on Product Label
Product
Lot Number
Quantity
Recall Reason
Product Distribution
ehlor-Tel time release capsules (chlorpheniramine maleate USP 12 mg), 1,000's
Garden (Hackensack, N.J.) Wollins (Farmingdale, N.Y.)
6954
448,000 capsules
Subpotent (81-96.3% of declared potency)
Michigan New Jersey New York Pennsylvania
Delfeta-Sed plus T steady tabs sustained release tablets (dl-methamphetamine hydrochloride USP 30 mg, amobarbital USP 120 mg, thyroid USP 48.6 mg), 30's
Eastern Research (Baltimore, Md.)
All lots
976,260 tablets
Drug efficacy study implementation
National
Deprol tablets (meprobamate NF 400 mg, benactyzine hydrochloride 1 mg), samples of 12's and 100's
Wallace (Cranbury, N.J.)
All starting 6E through 6L; all starting 7A and 7B through 7B536, 23-2-789 through 23-2-856
80,300,000 tablets
Subpotent (83-92% of declared benactyzine)
National
Oolamine injection (ammonium sulfate 0.75%, benzyl alcohol NF 0.75%, sodium chloride U$P 0.48%), 10 ml
Harvey (Philadelphia, Pa.)
All lots
All since 1939
Drug efficacy study implementation
National
Estrogenic substance natural injection 2 mg/ml, 10 ml and 30 ml
Taylor (Decatur, III.)
21179
15,830 ml
Subpotent (68.5-82.5% of declared potency
California Canada
Furacin gauze pads (nitrofurazone NF 0.2%), 12's
Eaton (Norwich, N. Y.)
665165 to 665197, 665208 to 665231
41,200 packages
Excessive residues of ethylene oxide
National
locort cream (hydrocortisone USP 1/4%, iodochlorhydroxyquin 3%), 10z
Doak (Westbury, N. Y.)
All lots
97 tubes
Su perpotent (126-132% of declared hydrocortisone)
Connecticut Indiana Massachusett s New Jersey New York Rhode Island
Canadian Pharmaceutical Association Survey Issued THE AVERAGE PRESCRIPTION drug price in Canada for 1968 was $3.67-an increase of 10 cents over 1967 and the lowest during the past three years. According to the Canadian Pharmaceutical Association's 27th Annual Survey of Retail Pharmacy, published in the October 1969 edition of The Canadian Pharmaceutical Journal, the 1968 average of $3.67 compares with $3.57 in 1967, $3.46 in 1966 and $3.32 in 1965. Sales in Canadian pharmacies during 1968 increa~ed 8.5 percent with the greatest increase in sales resulting from prescription receipts which increased 10.6 percent while other sales increased 7.6 percent according to the CPhA survey. The 1968 average number of prescriptions dispensed in the pharmacy annually increased 7.7 percent over 1967 to a total of 14,830. The survey also showed that the average hours per week a pharmacy was open dropped slightly-from 65 in 1967 to 64 in 1968-but that the average number of hours worked by the proprietor increased from 48 to 50 hours.
Know Your Suppliers Much has been said recently about "research," "product development," "quality control" and "professional services" offefled by the pharmaceutical industry. Evidenoe to support these activities has been often presented by the industry as a whole, but we feel that not ,e nough of us "really know" enough about many of the major prescription drug manufacturers, much less those firms that specialize in other types of pharmaceutical products and servioes. To present the "true personality" of a variety of different pharmaceutical companies-and we believe that each has its own personality just as each of us has a distinct personality-this Journal has offered to share the cost of publishing a series of four-page articles with various firms . In each of these features (see page 118) , readers will see the unique capabilities and seTvices of many firms whose products they use regularly. To be sure, som,e of the data will apply equally to all reputable firms, but even here, we hope the reader will better understand the American pharmaceutical industry without whose efforts we would not have many of the life-saving drugs we are able to provide to the public. The editorial content of each article is that of the firm and the selection of illustrations was made by the company. Thus, a careful review of each featured manufactur1er's presentation will truly reflect the achievements as well as the philosophy of that particular firm. We urge readership reaction to the series as it progress,es. The Editor
Vol. NS10, No.2, February 1970
117